News
Ustekinumab is more efficacious than vedolizumab or anti-TNFs as second- or third-line biologic therapy for perianal Crohn disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback